Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.
Latest from Mary Jo Laffler
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Citeline analysts offered deep dives into some of the data presented at the American Society of Clinical Oncology annual meeting, including both major highlights and some lesser-known finds.
As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
As the American Society of Clinical Oncology annual meeting drew to a close, Scrip spoke with industry execs about staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
The trial offers proof of concept for using Opdivo plus Yervoy as neoadjuvant treatment in melanoma; BMS notes a registrational trial is needed, but it is not clear which IO drugs will advance.